<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593056</url>
  </required_header>
  <id_info>
    <org_study_id>DUPLICATE-ROCKET AF</org_study_id>
    <nct_id>NCT04593056</nct_id>
  </id_info>
  <brief_title>Replication of the ROCKET-AF Anticoagulant Trial in Healthcare Claims Data</brief_title>
  <official_title>Replication of the ROCKET-AF Anticoagulant Trial in Healthcare Claims Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators are building an empirical evidence base for real world data through large-scale&#xD;
      replication of randomized controlled trials. The investigators' goal is to understand for&#xD;
      what types of clinical questions real world data analyses can be conducted with confidence&#xD;
      and how to implement such studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE&#xD;
      initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical&#xD;
      School. It is intended to replicate, as closely as is possible in healthcare insurance claims&#xD;
      data, the trial listed below/above. Although many features of the trial cannot be directly&#xD;
      replicated in healthcare claims, key design features, including outcomes, exposures, and&#xD;
      inclusion/exclusion criteria, were selected to proxy those features from the trial.&#xD;
      Randomization is also not replicable in healthcare claims data but was proxied through a&#xD;
      statistical balancing of measured covariates according to standard practice. Investigators&#xD;
      assume that the RCT provides the reference standard treatment effect estimate and that&#xD;
      failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims&#xD;
      data for replication for a range of possible reasons and does not provide information on the&#xD;
      validity of the original RCT finding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relative hazard of composite outcome of Stroke and Systemic Embolism</measure>
    <time_frame>[Time Frame: Through study completion (a median of 98-119 days)]</time_frame>
    <description>Relative hazard of composite outcome of Stroke and Systemic Embolism - Please refer to uploaded protocol for full definition due to size limitations.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">102636</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <description>Reference group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <description>Exposure group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Warfarin dispensing claim is used as the reference</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Rivaroxaban dispensing claim is used as the exposure</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will involve a new user, parallel group, cohort study design comparing&#xD;
        rivaroxaban to warfarin. The patients will be required to have continuous enrollment during&#xD;
        baseline period of 180 days before initiation of rivaroxaban or the comparator drug (cohort&#xD;
        entry date). Follow-up for the outcome, begins the day after drug initiation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Please see: https://drive.google.com/drive/folders/1WD618wrywYjEaXzfLTcuK-VCcnb6b-gV for&#xD;
        full code and algorithm definitions.&#xD;
&#xD;
        Eligible cohort entry dates: Market availability of rivaroxaban in the U.S. started on&#xD;
        November 4, 2011. For Marketscan: November 4, 2011 -Dec 31, 2018 (end of data&#xD;
        availability). For Optum: November 4, 2011 -Dec 31, 2019 (end of data availability). For&#xD;
        Medicare: November 4, 2011 -Dec 31, 2017 (end of data availability)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Patients 18 years of age or older&#xD;
&#xD;
          -  2. Non-valvular atrial fibrillation&#xD;
&#xD;
          -  3. Non-valvular atrial fibrillation 14 days or after the previous diagnosis of AF in&#xD;
             inclusion 2&#xD;
&#xD;
          -  4. History of prior ischemic stroke, TIA, systemic embolism or two or more of the&#xD;
             following risk factors:&#xD;
&#xD;
               -  4a. Heart failure and/or left ventricular ejection fraction ≤35%&#xD;
&#xD;
               -  4b. Hypertension (defined as use of antihypertensive medications within 6 months&#xD;
                  before the screening visit or persistent systolic blood pressure above 140 mmHg&#xD;
                  or diastolic blood pressure above 90 mmHg)&#xD;
&#xD;
               -  4c. Patients 75 years of age or older&#xD;
&#xD;
               -  4d. Diabetes mellitus (defined as a history of type 1 or type 2 diabetes mellitus&#xD;
                  or use of antidiabetic medications within 6 months before screening visit)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Cardiac-related conditions&#xD;
&#xD;
               -  1a. Hemodynamically significant mitral valve stenosis&#xD;
&#xD;
               -  1b. Prosthetic heart valve (annuloplasty with or without prosthetic ring,&#xD;
                  commissurotomy and/or valvuloplasty are permitted)&#xD;
&#xD;
               -  1e. Known presence of atrial myxoma or left ventricular thrombus&#xD;
&#xD;
               -  1f. Active endocarditis&#xD;
&#xD;
          -  2. Hemorrhage-related risk criteria&#xD;
&#xD;
               -  2a. Active internal bleeding&#xD;
&#xD;
               -  2b. History of or condition associated with increased bleeding risk including,&#xD;
                  but not limited to:&#xD;
&#xD;
                    -  Major surgical procedure or trauma within 30 days before the randomization&#xD;
                       visit&#xD;
&#xD;
                    -  Clinically significant gastrointestinal bleeding within 6 months before the&#xD;
                       randomization visit&#xD;
&#xD;
                    -  History of intracranial, intraocular, spinal, or atraumatic intra-articular&#xD;
                       bleeding&#xD;
&#xD;
                    -  Chronic hemorrhagic disorder&#xD;
&#xD;
                    -  Known intracranial neoplasm, arteriovenous malformation, or aneurysm&#xD;
&#xD;
               -  2d. Platelet count &lt; &lt;90,000/μL at the screening visit&#xD;
&#xD;
               -  2e. Sustained uncontrolled hypertension: systolic blood pressure ≥180 mmHg or&#xD;
                  diastolic blood pressure ≥100&#xD;
&#xD;
          -  3. Concomitant conditions and therapies&#xD;
&#xD;
               -  3a. Severe, disabling stroke (modified Rankin score of 4 to 5, inclusive) within&#xD;
                  3 months or any stroke within 14 days before the randomization visit&#xD;
&#xD;
               -  3b. Transient ischemic attack within 3 days before the randomization visit&#xD;
&#xD;
               -  3c. Indication for anticoagulant therapy for a condition other than atrial&#xD;
                  fibrillation (e.g., VTE)&#xD;
&#xD;
               -  3d. Treatment with:&#xD;
&#xD;
                    -  Aspirin &gt;100 mg daily&#xD;
&#xD;
                    -  Aspirin in combination with thienopyridines within 5 days before&#xD;
                       randomization&#xD;
&#xD;
                    -  Intravenous antiplatelets within 5 days before randomization&#xD;
&#xD;
                    -  Fibrinolytics within 10 days before randomization&#xD;
&#xD;
                    -  Note: Aspirin ≤100 mg monotherapy is allowed and thienopyridine monotherapy&#xD;
                       is allowed.&#xD;
&#xD;
               -  3f. Systemic treatment with a strong inhibitor of cytochrome P450 3A4, such as&#xD;
                  ketoconazole or protease inhibitors, within 4 days before randomization, or&#xD;
                  planned treatment during the time period of the study&#xD;
&#xD;
               -  3g. Treatment with a strong inducer of cytochrome P450 3A4, such as&#xD;
                  rifampin/rifampicin, within 4 days before randomization, or planned treatment&#xD;
                  during the time period of the study&#xD;
&#xD;
               -  3h. Anemia (hemoglobin &lt;10 g/dL) at the screening visit&#xD;
&#xD;
               -  3i. Pregnancy or breast-feeding&#xD;
&#xD;
               -  3k. Known HIV infection at time of screening&#xD;
&#xD;
               -  3l. Calculated CLCR &lt;30 mL/min at the screening visit (refer to Attachment 4 for&#xD;
                  calculating CLCR)&#xD;
&#xD;
               -  3m. Known significant liver disease (e.g., acute clinical hepatitis, chronic&#xD;
                  active hepatitis, cirrhosis), or ALT &gt;3 x the ULN&#xD;
&#xD;
          -  4. Study participation and follow-up-related criteria&#xD;
&#xD;
               -  4a. Serious concomitant illness associated with a life expectancy of less than 2&#xD;
                  years&#xD;
&#xD;
               -  4b. Drug addiction or alcohol abuse within 3 years before the randomization visit&#xD;
&#xD;
               -  4f. Inability or unwillingness to comply with study-related procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jessica Franklin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham And Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Jessica Franklin</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT04593056/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

